Amino Acid Mix Supercharges Lipid Nanoparticle Delivery for mRNA and CRISPR Therapies

Scientists have discovered that a simple mix of three amino acids can greatly improve how well lipid‑nanoparticle (LNP)–based therapies work in the body. These LNPs are tiny fat‑like packages used to carry mRNA or CRISPR components into cells, and they are already at the heart of new vaccines and gene‑editing treatments. The new finding suggests that pairing standard LNPs with this amino acid cocktail can boost how much of the genetic material gets inside target cells, without changing the nanoparticle itself.

The amino acids involved are methionine, arginine, and serine. In animal models, giving these amino acids at the same time as the LNP injection increased mRNA expression by about 5‑ to 20‑fold, depending on the cell type and delivery route. The effect was seen after intramuscular, intratracheal, and intravenous dosing, which means it is not limited to a single organ or administration method. The team believes that the amino acids help cells take in the LNPs more easily, likely by promoting a specific type of internalization called clathrin‑independent carrier‑mediated endocytosis.

In one experiment, researchers used LNPs to deliver a gene that encodes a growth hormone to the liver in mice with acute liver injury caused by acetaminophen. Without the amino acid mix, about 33% of the animals survived, but when the same LNP dose was combined with the cocktail, survival jumped to 100%. In another experiment, LNPs were used to deliver CRISPR components to the lungs, where they aimed to edit a gene in lung cells. Standard LNP delivery led to roughly 20% to 30% editing, but adding the amino acids pushed editing up to about 85% to 90% after a single dose.

These results are important because they suggest that improving cellular uptake may be as critical as redesigning the nanoparticle. Many existing LNPs work well in the lab, where cells sit in nutrient‑rich media, but perform less efficiently in the body. The amino acid cocktail seems to help bridge that gap by making the target cells more receptive to the LNPs. That could make it easier to repurpose existing LNP formulations for new diseases or to achieve sufficient gene expression with lower or less frequent doses.

In the context of cancer, the idea has interesting potential implications. LNPs are being explored for mRNA cancer vaccines, intratumoral delivery of immune‑stimulating genes, and CRISPR‑based strategies to disrupt survival genes or resistance pathways in tumors. If the amino acid mix can increase how much of the mRNA or CRISPR cargo reaches the intended cells, it might improve the strength of the immune response, enhance killing of tumor cells, or make gene editing more efficient. However, cancer poses extra challenges, including a dense tumor microenvironment, poor blood supply, and the risk of delivering more payload to healthy tissues if uptake is boosted in a non‑selective way.

Source.